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Insulin resistance is a syndrome that affects multiple
insulin target tissues, each having different biological
functions regulated by insulin. A remaining question
is to mechanistically explain how an insulin target
cell/tissue can be insulin resistant in one biological
function and insulin sensitive in another at the same
time. Here, we provide evidence that in pancreatic
b cells, knockdown of PI3K-C2a expression results
in rerouting of the insulin signal from insulin receptor
(IR)-B/PI3K-C2a/PKB-mediated metabolic signaling
to IR-B/Shc/ERK-mediated mitogenic signaling,
which allows the b cell to switch from a highly
glucose-responsive, differentiated state to a prolifer-
ative state. Our data suggest the existence of IR-
cascade-selective insulin resistance, which allows
rerouting of the insulin signal within the same target
cell. Hence, factors involved in the rerouting of the in-
sulin signal represent tentative therapeutic targets in
the treatment of insulin resistance.INTRODUCTION
An unsolved paradoxwith regard to insulin receptor (IR) signaling
is the coexistence of insulin resistance and insulin sensitivity in
the same insulin target cell/tissue. With regard to the pancreatic
b cell, it has been demonstrated that under conditions of insulin
resistance provoked by a high-fat diet, insulin signaling in b cells
is required for a compensatory increase in pancreatic b cell mass
by proliferation (Okada et al., 2007). This observation raised the
question of how the pancreatic b cell can switch from an insulin-
dependent differentiated state that is glucose sensitive in terms
of insulin secretion and biosynthesis to an insulin-dependent
proliferative state under conditions of insulin resistance.
Increasing pancreatic b cell mass is of vital importance inresponse to relative insulin deficiency in physiology (e.g., preg-
nancy) or in the pre-state of type 2 diabetes mellitus (T2DM)
(e.g., obesity) including insulin resistance. Several factors have
been shown to stimulate b cell proliferation, including innervation
by the autonomous nervous system (Imai et al., 2008) as well as
humoral factors such as glucose, incretins (GLP-1, GIP), adipo-
kines (adiponectin, leptin), growth hormones (GHs; prolactin,
placental lactogen), and insulin (for review, see Leibiger et al.,
2008; Liu et al., 2009; Kulkarni, 2005; Vasavada et al., 2006; Yesil
and Lammert, 2008). Interestingly, among these factors, insulin
has also been shown to contribute to the differentiated b cell
phenotype by, for example, regulating expression and nuclear
activity of transcription factors Pdx-1/Ipf-1, FoxO1, and FoxA2
(Leibiger et al., 2008).
We have recently shown that signaling via insulin receptor B
(IR-B) and phosphatidylinositol 3-kinase (PI3K) class II member
PI3K-C2a is required for glucose-stimulated insulin secretion
(Leibiger et al., 2010a), thus keeping the b cell in a glucose-sen-
sitive, differentiated state. PI3K-C2a has been shown to be
involved in various steps of signal transduction and membrane
trafficking (Campa et al., 2015). We now demonstrate an in-
crease in proliferation of primary rodent and human b cells
when knocking down PI3K-C2a. This was unexpected, because
knockdown of PI3K-C2a has been shown to increase cell death
in other cell systems (Elis et al., 2008; Kang et al., 2005; Ng et al.,
2009). Our published data demonstrate that different insulin
signaling cascades coexist in b cells, thus allowing different se-
lective biological effects (Leibiger et al., 2008, 2010b). In this
context, our new data suggest the existence of IR-cascade-
selective insulin resistance, which allows rerouting of the insulin
signal in the same cell. We propose that insulin resistance in one
signaling cascade, here via IR-B/PI3K-C2a, leads to a partial
loss of the differentiated, glucose-responsive state of the b cell
but at the same time promotes b cell proliferation by a different
signaling cascade. Thus, PI3K-C2a represents a key regulatory
factor that allows the b cell to turn from differentiation (PI3K-C2a
available) to proliferation (PI3K-C2a unavailable) in response to
insulin.Cell Reports 13, 15–22, October 6, 2015 ª2015 The Authors 15
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Figure 1. Knockdown of PI3K-C2a Leads to an Increase in Pancreatic b Cell Proliferation
(A and B) Knockdown of PI3K-C2a in MIN6m9 cells leads to an increase in cell confluence. Increase in cell confluence 96 hr versus 48 hr after start of transfection
(A) and over time (B).
(C) Representative western blot demonstrating knockdown of PI3K-C2a with two different siRNAs.
(D–F) Knockdown of PI3K-C2a leads to increased proliferation of MIN6m9 cells (D), primary mouse b cells (E), and primary human b cells (F) measured by EdU
incorporation.
(G and H) Knockdown of PI3K-C2a leads to protection against apoptosis induced by H2O2 (G) and staurosporine (H).
All data are expressed as mean ± SEM (n = 3). **p < 0.01; ***p < 0.001. See also Figures S1 and S2.RESULTS
Knockdown of PI3K-C2a Leads to an Increase
in Pancreatic b Cell Proliferation
Our previous study showed that insulin signaling via IR-B and
PI3K-C2a keeps the pancreatic b cell in a differentiated,
glucose-responsive state by, among other things, regulating
the expression of the b cell glucose sensor glucokinase (Leibiger
et al., 2010a). To our surprise, small interfering RNA (siRNA)-
mediated knockdown of PI3K-C2a expression led to a signifi-
cant increase in the confluence of insulin producing MIN6 cells
by two independent siRNAs against PI3K-C2a already 96 hr after
transfection with the siRNA. This effect was even more pro-
nounced 120 hr after start of transfection (Figures 1A–1C). To
test whether this increase in cell confluence was due to
increased cell proliferation, we studied the incorporation of
labeled DNA precursors by 5-ethynyl-20-deoxyuridine (EdU)
treatment. Four days after transfection with siRNA against
PI3K-C2a, MIN6 cells were treated with EdU for 1 hr, while
mouse and human pancreatic islet cells were treated with EdU
for 24 hr. Primary b cells were identified by immunostaining
against insulin C-peptide. Knockdown of PI3K-C2a led to a
1.5-fold increase in proliferation in MIN6 cells and to a more16 Cell Reports 13, 15–22, October 6, 2015 ª2015 The Authorsthan 2-fold increase in proliferation in primary b cells (Figures
1D–1F and S1). Because knockdown of PI3K-C2a has been
shown to lead to increased cell death in other cell systems
(Elis et al., 2008; Kang et al., 2005; Ng et al., 2009) and the
now observed increase in cell proliferation could reflect a
compensatory response to b cell apoptosis, we next analyzed
the effect of PI3K-C2a knockdown on stimulus-induced
apoptosis in MIN6 cells. Four days after start of transfection
with siRNA against PI3K-C2a, MIN6 cells were treated with
either 20 mM H2O2 or 6 mM staurosporine for 16 hr. The cell
apoptosis rate was determined by triple staining with Hoechst
33342, propidium iodide, and Alexa 488/annexin V, where Alexa
488/annexin V-positive/propidium-iodide-negative stained cells
were considered apoptotic. As shown in Figures 1G, 1H, and
S2, knockdown of PI3K-C2a expression led to protection
against stimulus-induced apoptosis rather than an increase in
the apoptosis rate.
Knockdown of PI3K-C2a Leads to Decreased Metabolic
and Increased Mitogenic Insulin Signaling
We have previously shown that knockdown of PI3K-C2a in
pancreatic b cells abolishes insulin-stimulated activation of
PKBa, which affected the phosphorylation of PKB substrate
TBC1D4, a Rab GTPase-activating protein (Leibiger et al.,
2010a). It is noteworthy that knockdown of PI3K-C2a did not
affect insulin-stimulated activation of PKBb or of PKBg in b cells.
Consequently, we wanted to know whether knockdown of PI3K-
C2a would affect other PKB substrates that potentially could be
involved in b cell proliferation, such as FoxO1 and TSC2. As
shown in Figure S3A, knockdown of PI3K-C2a led to an increase
in FoxO1 activity as indicated by its decrease in phosphorylation.
This, together with the observed decrease in phosphorylation of
TSC2 (Figure S3B), is not in line with an increase in b cell prolif-
eration (Bartolome´ et al., 2010; Okamoto et al., 2006). Because
knockdown of PI3K-C2a leads to a decrease in the expression
of glucokinase (GK) and GK has been suggested to play a role
in b cell proliferation (Terauchi et al., 2007), we next analyzed
whether knockdown of GK affects b cell proliferation and sur-
vival. siRNA-mediated knockdown of GK protein levels to 35%
in MIN6 cells did not affect cell confluence or stimulus-induced
apoptosis in these cells (Figures S3C–S3E). These data, together
with our earlier published data (Leibiger et al., 2010a), demon-
strate that PI3K-C2a knockdown results in decreased insulin
signaling via the metabolic branch of signal transduction. To
test whether the knockdown leads to an increase in mitogenic
signaling, we analyzed the effect of PI3K-C2a knockdown in
MIN6 cells on the activity of ERK1/2 as well as on the expression
of the proto-oncogene c-fos. As shown in Figures 2A–2C, the
reduced expression of PI3K-C2a led to a 1.3-fold increase in
ERK1/2 phosphorylation as well as an increase in c-fos promoter
activity and c-fos protein expression.
The Proliferative Effect of PI3K-C2a Knockdown
Is IR-B Dependent
The pancreatic b cell expresses both isoforms of the insulin
receptor, i.e., IR-A and IR-B (Leibiger et al., 2001), and both iso-
forms signal simultaneously by utilizing different signaling cas-
cades (Leibiger et al., 2001; Uhles et al., 2003, 2007). Because
mitogenic insulin signaling has been shown to be more often
associated with IR-A (reviewed in Belfiore et al., 2009), we
wanted to know whether PI3K-C2a knockdown results in a
switch from metabolic signaling via IR-B to mitogenic signaling
involving IR-A. To study which IR isoform contributes to b cell
proliferation, we first made use of antibodies that block signaling
via IR. A pan-antibody that abolishes signaling through both IR
isoforms suppressed the proliferative effect of PI3K-C2a knock-
down in both mouse and human b cells (Figures 2D and 2E).
Interestingly, employing an IR-B-selective blocking antibody
also abolished b cell proliferation (Figures 2F and 2G). Because
there is no IR-A-selective blocking antibody available, we used
aptamers that selectively block signaling via each IR isoform.
In Figure S3F, we demonstrate that aptamer-A abolishes insu-
lin-induced activation (i.e., auto-phosphorylation) of IR-A, but
not IR-B, and vice versa that aptamer-B abolishes insulin-
induced activation of IR-B, but not IR-A. Employing these ap-
tamers on cells that were treated with either control siRNA or
siRNA against PI3K-C2a, we observed that blocking insulin
signaling via IR-A did not abolish the proliferative effect of
PI3K-C2a knockdown, while blocking signaling via IR-B did (Fig-
ure 2H). This suggested that PI3K-C2a knockdown does not lead
to a switch from IR-B- to IR-A-mediated signaling but results in arerouting from metabolic IR-B signaling to mitogenic IR-B
signaling. To test this, we employed reporter gene constructs
that report on the activity of these two pathways. While b cell
GK promoter-driven GFP (bGK.GFP) expression serves as a
readout for IR-B-mediated metabolic signaling via IR-B/PI3K-
C2a/PKBa (Leibiger et al., 2010a), c-fos promoter-driven DsRed
(cfos.DsRed) expression serves as a readout for IR-B-mediated
mitogenic signaling via IR-B/Shc/ERK (Uhles et al., 2007). To
ensure expression of both reporters in the same cell, we trans-
fected cells with plasmids that contain both expression cas-
settes. We co-transfected cells with the reporter plasmid and
either control siRNA or C2a2-siRNA and combined this with or
without insulin stimulation. Indeed, knockdown of PI3K-C2a
led to a more pronounced activation of the mitogenic signaling
cascade, resulting in increased c-fos promoter-activated DsRed
expression, while the metabolic signaling leading to GK pro-
moter-driven GFP expression was suppressed (Figure 2I).
Knockdown of PI3K-C2a Leads to Increased IR-B/Shc
Interaction
To mechanistically explain how the knockdown of PI3K-C2a
expression results in pronounced IR-B-mediated mitogenic
signaling, we studied the association of IR-B with the adaptor
protein Shc in two independent ways. First, we studied this asso-
ciation in cells overexpressing myc-tagged IR-B in co-immuno-
precipitates using anti-myc antibodies. PI3K-C2a knockdown
led to a 1.8-fold higher association of IR-B with Shc compared
to control (Figures 3A and 3B). Second, we studied the interac-
tion between IR-B and Shc by fluorescence resonance energy
transfer (FRET). MIN6 cells were co-tranfected with pIR-B-
mVenus, pShc-mCFP, and either control siRNA or C2a2-siRNA.
PI3K-C2a knockdown led to a 2.5-fold higher FRET efficiency
between IR-B and Shc compared to control siRNA-transfected
cells (Figure 3C). Next, we wanted to know whether this shift in
interaction between IR-B with PI3K-C2a and IR-B with Shc
also occurs under conditions that mimic a diabetic situation,
e.g., prolonged hyperglycemia. Therefore we incubated cells
co-expressing either IR-B-mVenus with PI3K-C2a-mCerulean
or IR-B-mVenus with Shc-mCFP at different glucose concentra-
tions and measured FRET efficiency between IR-B and either
PI3K-C2a or Shc. As shown in Figure 3D, an increase in glucose
concentration resulted in a higher association of IR-B with Shc.
The same culture conditions also led to an increase in cell prolif-
eration (Figure 3E).
To establish the relevance of our rerouting model in vivo, we
chose the leptin-deficient ob/ob mouse. Three-month-old
ob/ob mice are hyperinsulinemic and hyperglycemic and have
an increased b cell mass due to b cell proliferation, and in addi-
tion to being overall insulin resistant, they show insulin resistance
at the islet/b cell level in the metabolic branch of insulin signaling
(A˚vall et al., 2015; Ilegems et al., 2013; Lindstro¨m, 2007). West-
ern blot analysis of islet lysates show a decreased expression
of GK and an increased expression of c-fos in ob/ob islets
compared to islets from control mice (Figures 4A–4C), thus being
in agreement with a rerouting of insulin signaling. An increased
mitogenic signaling was further supported by a higher ERK1/2
activity in ob/ob islets compared to controls (Figures 4D and
4E). Both western blot analysis and immunohistochemistryCell Reports 13, 15–22, October 6, 2015 ª2015 The Authors 17
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Figure 2. Knockdown of PI3K-C2a Leads to Decreased Metabolic and Increased Mitogenic Insulin Signaling, and the Proliferative Effect of
PI3K-C2a Knockdown Is IR-B Dependent
(A) Knockdown of PI3K-C2a leads to increased ERK1/2 phosphorylation at Thr202 and Tyr204 evaluated by western blotting.
(B) Knockdown of PI3K-C2a leads to increased c-fos promoter activity evaluated by luciferase assay.
(C) Knockdown of PI3K-C2a leads to increased c-fos protein levels evaluated by western blot.
(D and E) The proliferative effect of PI3K-C2a knockdown is insulin/IR dependent and can be blocked by antibodies that block signaling via both IRs. Primary
mouse b cells (D) and primary human b cells (E) were treated with antibodies during EdU incorporation.
(F and G) The proliferative effect of PI3K-C2a knockdown is IR-B dependent. Primary mouse b cells (F) and primary human b cells (G) were treated with antibodies
blocking signaling through IR-B during EdU incorporation.
(H) The proliferative effect of PI3K-C2a knockdown can be blocked by aptamers blocking signaling via IR-B. Primary human b cells were treated with blocking
aptamers during EdU incorporation.
(I) Knockdown of PI3K-C2a results in a more pronounced activation of the mitogenic signaling cascade leading to c-fos promoter-activated DsRed expression
(cfos.DsRed, solid bars), while metabolic signaling leading to glucokinase promoter-driven GFP expression (bGK.GFP, open bars) is diminished.
All data are expressed as mean ± SEM (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S3.
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Figure 3. Knockdown of PI3K-C2a Leads to
Increased IR-B/Shc Interaction
(A and B) Knockdown of PI3K-C2a leads to
increased interaction between overexpressedmyc-
tagged IR-B and endogenous Shc. The interaction
was evaluated by western blot after immunopre-
cipitation with myc-antibodies (A). Data from three
individual experiments are shown. The left-most
lane shows Shc bands from a MIN6 cell lysate. (B)
Quantification of IR-B/Shc interaction from (A). Data
are expressed as mean ± SEM (n = 3).
(C and D) Knockdown of PI3K-C2a (C) or hyper-
glycemic culture conditions (D) lead to increased
interaction between IR-B and Shc in MIN6m9 cells
analyzed by fluorescence resonance energy trans-
fer (FRET). Data are expressed as mean ± SEM
(n = 10).
(E) Hyperglycemic culture conditions of MIN6m9
cells lead to an increase in cell proliferation. Data
are expressed as mean ± SEM (n = 24).
*p < 0.05; **p < 0.01; ***p < 0.001.revealed decreased expression levels of PI3K-C2a in ob/ob islet/
b cells compared to controls (Figures 4D, 4F, and S4). Moreover,
western blot analysis showed an increase in Shc expression in
ob/ob islets (Figures 4D and 4G). It is noteworthy, that prolifer-
ating b cells (cells positive for Ki67 and insulin) in ob/ob islets
showed even lower levels of PI3K-C2a (Figure S4). Finally, we
analyzed the association of PI3K-C2a, class Ia PI3K adaptor
protein p85 and Shc with insulin receptors in ob/ob and control
islet lysates. Although we failed to detect PI3K-C2a in IR co-im-
munoprecipitates, we observed an increased association of IR
with p85 and Shc in ob/ob islets compared to controls (Figures
4H–4J).
DISCUSSION
A remaining question in the insulin-signaling field is to mechanis-
tically explain how an insulin target cell/tissue can be insulin
resistant in one biological function and insulin sensitive in
another at the same time. A classical example is the paradox
of selective insulin resistance in the liver resulting in insulin’s
inability to suppress glucose output while at the same time
showing increased insulin-stimulated lipogenesis (discussed in
Brown and Goldstein, 2008). Similar phenotypes have been
observed for other cell/tissue systems (Book and Dunaif, 1999;
Jiang et al., 1999; Li et al., 2010; Pandolfi et al., 2005), including
the pancreatic b cell. With regard to the latter, data by Kulkarni’s
group demonstrated that under conditions of insulin resistance
provoked by a high-fat diet, b cell IR-mediated signaling is
required for compensatory increase in pancreatic b cell mass
by b cell proliferation (Okada et al., 2007). This observation raised
the question of how the pancreatic b cell can switch from an in-
sulin-dependent differentiated state to an insulin-dependentCell Reports 13, 15–proliferative state under conditions of insu-
lin resistance. Although it is well docu-
mented that insulin can activate two
different branches in signal transduction,
namely the metabolic branch involvingPKB and PKC isoforms and the mitogenic branch involving the
MAP kinase cascade, it remains unclear whether and mechanis-
tically how the same insulin target cell can switch between these
two modes. Here, we provide evidence that creating insulin
resistance in IR-B/PI3K-C2a/PKBa-mediated metabolic sig-
naling, a pathway that maintains the b cell glucose-responsive
state, leads to rerouting of the insulin signal to IR-B/Shc/ERK-
mediated mitogenic signaling, resulting in increased c-fos
expression and pancreatic b cell proliferation. This was unex-
pected, because mitogenic insulin signaling has been mostly
associatedwith the IR-A isoform (Belfiore et al., 2009). Moreover,
data obtained in engineered b cell lines expressing only one or
the other IR isoform (Rec A and Rec B) showed a higher prolifer-
ative activity for the IR-A-expressing cells (Bartolome´ et al.,
2010). Data on insulin-dependent b cell proliferation from
different laboratories demonstrate the involvement of signaling
components such as IRS2, PKB, TSC2, p70s6k, and FoxO1
(Bartolome´ et al., 2010; Bernal-Mizrachi et al., 2001; Cantley
et al., 2007; Fatrai et al., 2006; Hashimoto et al., 2006; Kubota
et al., 2004). It is noteworthy that knockdown of PI3K-C2a still al-
lows insulin-stimulated action of PKBb and PKBg and basal ac-
tivity of PKBa. Within this scenario, we observed an increased
activity of FoxO1, which is in disagreement with increased prolif-
erative activity. Under these conditions, knockdown of PI3K-C2a
leads to a decrease in TSC2 activity, which makes the involve-
ment of the downstream components mTORC1/p70s6k in b
cell proliferation unlikely.
While the siRNA-mediated knockdown of PI3K-C2a expres-
sion serves as an example for rerouting of b cell IR-mediated
signaling, this model bears relevance to T2DM. Data provided
by Dominguez and co-authors (Dominguez et al., 2011) show a
decreased pancreatic islet expression/availability of PI3K-C2a22, October 6, 2015 ª2015 The Authors 19
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Figure 4. Decreased PI3K-C2a and Increased Shc Protein Levels in ob/ob Mice
(A–C) GK protein levels are decreased and c-fos protein levels are increased in islets of ob/ob mice compared to age-matched control mice. (A) Western blot.
(B and C) Quantification of c-fos (B) and GK (C) protein levels normalized to a-tubulin levels.
(D–G) PI3K-C2a protein levels are decreased and Shc protein levels and ERK1/2 phosphorylation levels are increased in ob/ob islets compared to controls.
(D) Western blot. (E) Quantification of ERK1/2 phosphorylation levels. (F and G) Quantification of PI3K-C2a (F) and Shc (G) protein levels normalized to a-tubulin
levels.
(A–G) Data are expressed as mean ± SEM (n = 3–5). *p < 0.05.
(H–J) Increased association of IR with p85 and Shc in co-immunoprecipitation analysis from ob/ob islet lysates. (H) Western blot. (I and J) Quantification of p85
(I) and Shc (J) protein levels in IR immunoprecipitates. Data are expressed as mean ± SEM (n = 2). *p < 0.05.
See also Figure S4.in patients with T2DM. This is in agreement with our data,
mimicking T2DM-like conditions in terms of hyperglycemia,
demonstrating a shift from an IR-B/PI3K-C2a-mediated meta-
bolic signaling to an IR-B/Shc-mediated mitogenic signaling
cascade leading to increased b cell proliferation. Furthermore,
pancreatic islets obtained from 3-month-old ob/ob mice, which20 Cell Reports 13, 15–22, October 6, 2015 ª2015 The Authorsare insulin resistant in the metabolic branch of insulin signaling,
demonstrate a decrease in GK expression (reflecting a
decreased metabolic signaling), an increase in c-fos expression
and ERK activity (reflecting an increased mitogenic signaling), a
decreased expression of PI3K-C2a, an increased expression of
Shc and an increased association of insulin receptors with PI3K
class Ia adaptor protein p85 as well as with Shc, all data being in
agreement with the above proposed model.
Our data thus provide evidence that insulin resistance within
one signaling cascade and increased insulin responsiveness
within another can indeed coexist within the same insulin target
tissue/cell and give support to the concept of signaling-
cascade-selective insulin resistance. Hence, factors involved in
the rerouting of the insulin signal represent tentative therapeutic
targets in the treatment of insulin resistance.
EXPERIMENTAL PROCEDURES
Aptamers and siRNA-Mediated Knockdown
DNA-based aptamers that selectively recognize and block insulin receptors,
i.e., IR-A-aptamer IR-A55 and IR-B-aptamer IRB-N11, were synthesized and
screened at POSTECH. siRNAs against mouse PI3K-C2a (Pik3c2a: siRNA1ID
68525, siRNA2ID 68710), siRNA against human PI3K-C2a (PIK3C2A: s10508),
and validated non-targeting negative control (AM4613) were purchased from
Ambion (Applied Biosystems/Ambion). siRNA against mouse glucokinase
(SI01010359) was purchased from QIAGEN.
EdU Incorporation
Cell proliferation measurements were performed utilizing the Click-iT EdU
Alexa 488 HCS Assay kit (Invitrogen) following themanufacturer’s instructions.
Western Blotting
The following primary antibodies were used: rabbit monoclonal phospho-tu-
berin/TSC2 (Thr1462), rabbit polyclonal tuberin/TSC2, rabbit polyclonal phos-
pho-FoxO1 (Ser256), rabbit monoclonal FoxO1, rabbit monoclonal phospho-
p44/42 MAPK (Erk1/2 Thr202/Tyr204), rabbit polyclonal p44/42 MAPK (Erk1/
2), rabbit polyclonal c-fos, mouse monoclonal and rabbit monoclonal insulin
receptor b, rabbit monoclonal PI3K class II a, rabbit monoclonal Shc, and rab-
bit monoclonal PI3K p85 (Cell Signaling Technology); rabbit polyclonal gluco-
kinase andmousemonoclonal GAPDH (Abcam); rabbit polyclonal p-insulin Rb
(Tyr 1162/1163) (Santa Cruz Biotechnology); mouse monoclonal Shc (BD
Transduction Laboratories); and mouse monoclonal a-tubulin (Sigma).
Immunoprecipitation
Immunoprecipitation was performed using protein A/G Plus agarose (Santa
Cruz Biotechnology) and the following antibodies: mouse monoclonal anti-
body against c-myc (Santa Cruz Biotechnology), mouse monoclonal IR b anti-
body, and rabbit monoclonal IR b antibodies (both from Cell Signaling
Technology).
FRET Analysis by Acceptor Photobleaching
FRET analysis by acceptor photobleaching was performed using a Leica TCS-
SP2 confocal microscope as described in Leibiger et al. (2010a).
All mouse and human islet experiments were approved by the regional
ethical review boards in Uppsala and in Stockholm (Sweden). Additional
experimental procedures are described in Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.08.058.
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